Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make an impact at a globally recognised event and contribute to advancing multidisciplinary oncology care
The congress has now opened its doors in Paris, France! Join us to share your expertise with lung cancer specialists from around the world and help shape the future of lung cancer treatment!
Submit your research for MAP 2025 by 10 June. Contribute to advancing the understanding of the molecular foundations of cancer to enable precision oncology
Cutting-edge science, expert discussions, networking and innovations in breast cancer care await in Munich or online
Prof. Cervantes, Prof. Ben-Aharon, and Prof. Seufferlein explain why this is a must for GI oncology experts. Gain visibility, engage, and connect
Meet us in Vienna, or online, and gain insights, network, and contribute to meaningful discussions shaping the field
Be the force driving innovation in cancer drug development and make the latest advances in early clinical trials accessible to everyone in Asia
Online application is open until 1 April 2025
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
Detecting ctDNA and a simple four-component scoring system showed some predictive value, but require prospective validation
A model implemented by a non-profit organisation exemplifies how virtual consultation and follow-up of patients with rare cancer can facilitate continuity of care
Newly presented phase III trial and real-world findings reassure on the use of the gamma secretase inhibitor
While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability
New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer
Studies evaluate the efficacy and safety of promising agents including adagrasib and fulzerasib
Phase III data in metastatic NSCLC support an alternative route of administering immunotherapy, which may have an impact on patients’ preferences and cancer care costs
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events
ESMO would like to thank the Gyógyulj Velünk Egyesület (GYVE) for providing translation in the Hungarian language
Evidence for efficacy is based on the results from the ECHELON-3 study
Results from two trials could expand current options for patients with EGFR or HER2-activating mutations progressing on tyrosine kinase inhibitors
According to Heine H. Hansen Award winner, Prof. Keith Kerr, pathologists can help translate scientific understanding into clinical practice
New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer
Evidence for efficacy is based on the results from the ECHELON-3 study
Biomarker analyses from the CheckMate 649 study
Findings from the MANIFEST-2 study
Findings from the TROPiCS-04 study
New indication concerns the management of adult patients with unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer
Evidence for efficacy is based on the results from the ReNeu study
Findings from machine learning-based and population-level electronic health record data-based emulation of landmark phase III randomised clinical trials in oncology
Findings from a population-based study
The European Lung Cancer Congress 2025 is the event dedicated to the prevention, diagnosis, and management of thoracic malignancies
The ESMO Sarcoma and Rare Cancers Congress 2025, to be held from 20-22 March in Lugano, Switzerland, will be the convergence point for world-renowned experts to present and discuss developments in the diagnosis and treatment of rare solid tumours, going through their peculiar biology and molecular classification, while also addressing the methodological, organisational, and policy challenges that characterise this oncological area and its high unmet needs
Experts predict death rates from all cancers for the EU and UK for 2025
The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new targets, tumour-agnostic drug development, the role of artificial intelligence in drug development, radiotheranostics and cell therapies for solid tumours
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The European Society for Medical Oncology (ESMO) announced today that the recipient of the 2025 Heine H. Hansen Award is Keith Kerr, Consultant Pathologist for NHS Grampian and Honorary Chair in Pulmonary Pathology at the University of Aberdeen in Scotland
Burnout is an increasingly pressing concern for the oncology community
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide
The nomination process for the 2025 ESMO Society Awards is now open
The European Society for Medical Oncology (ESMO) has announced today that the recipient of the 2025 TAT Honorary Award is Philippe Bedard
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
France
Switzerland
Peru
Germany
Netherlands
Austria
Spain
Hong Kong SAR, China
Czech Republic
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
Analytics cookies help us improve our website by collecting and reporting information on its usage.
We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.
